FIELD: biotechnology.
SUBSTANCE: options of a tetravalent antibody that specifically binds to human PSGL-1 are proposed. Tetravalent antibodies contain dimer of two monomers, wherein each monomer contains two variable domains of a light chain and two variable domains of a heavy chain. Isolated polynucleotide encoding the antibody, an expression vector and a host cell including the specified polynucleotide are also proposed. A method for producing a tetravalent antibody, including the cultivation of the specified host cell, is also proposed. In addition, the invention relates to pharmaceutical compositions, kits and methods for the treatment of T-cell-mediated inflammatory diseases or the treatment of an individual in need of transfusion or transplantation, using the specified antibodies.
EFFECT: invention makes it possible to obtain tetravalent antibodies to PSGL-1, independent of cross-linker/FcR-expressing cells, which demonstrate increased efficiency compared to divalent antibodies
58 cl, 5 dwg, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| COVALENT DIABODIES AND USE THEREOF | 2009 |
|
RU2744176C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| ANTIBODIES AGAINST E-SELECTIN, COMPOSITIONS AND METHODS OF USE | 2021 |
|
RU2805176C1 |
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
